Pre-Operative PARPi and Irradiation (POPI) in Women with an Incomplete Response to Neo Adjuvant Chemotherapy (NAC) for Breast Cancer.

Inclusion Criteria
Patients must have histologically confirmed (by routine H&E staining) adenocarcinoma of the breast with confirmed nodal metastasis
Patients must have an axillary nodal evaluation by fine needle aspiration (FNA), sentinel node biopsy (SNB) or nodal dissection
Patient must have had a bilateral mammogram prior to NAC unless there is only one breast
Patient must have a Medical Oncology consult and be recommended to receive neoadjuvant chemotherapy for a stage IIB through IV carcinoma
Patients must not have received prior radiation therapy to the involved breast at any time for any reason
Patient must have a history and physical within 2 weeks prior to the start of any protocol therapy (radiation and veliparib)
Patient must have > 1.0 cm residual in-breast cancer and/or clinically positive residual nodal disease
No other prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or any other cancer from which the patient has been disease-free for 5 years
Patients must not have a serious medical or psychiatric illness which prevents informed consent or compliance with treatment
Patients must have a performance status 0 or 1 by ECOG criteria (Appendix I)
Exclusion Criteria
Patients with squamous, or metaplastic carcinomas or sarcomas of the breast
Women who have a investigational therapy, was less than 14 days prior to protocol therapy (radiation and veliparib)
Bisphosphonates, hormone modification therapy, and trastuzumab are permitted without restriction
Unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or prior anti-cancer treatment
Pregnant or breast-feeding
Clinically significant and uncontrolled major cardiac, respiratory, renal, hepatic, gastrointestinal, hematologic or neurological/psychiatric disease or disorder
Unable to swallow and retain oral medications
History of seizure disorder
Known contraindication to enhanced MRI and CT
Previous enrollment on another study involving the investigation of veliparib (ABT- 888), with the exception of receiving a single dose of study drug
Consideration by the Investigator, for any reason, that the subject is an unsuitable candidate to receive veliparib (ABT-888) and/or breast irradiation